Lifeboat Foundation

In a study from the University of Auckland, scientists found a drug that can increase life span. The age-old quest for immortality has taken a step forward. The team that long-term treatment of healthy mice from middle age (one year) with a drug currently used to treat cancer can increase their lifespan by an average of 10% to around three years.

Tidbits:

This current experiment is 3 million dollars.

Continue reading “Rapamycin, mTert, HSCT, Senolytic First Robust Rejuvenation Trial | Dr Aubrey de Grey 2 Ep 2” »

Epigenetic Leaderboard The Rejuvenation Olympics – where you win by never crossing the finish line See How You Rank Top 15 largest age reversals validated by phenotypically trained epigenetic methylation algorithms Rank Name % Improved From Baseline Chronological Age Baseline PACE PACE Of Aging Now (Mean Of 3 Tests) Managing Doctor 1 Bryan […].

The 2020s are the nascent era of Drug discovery sped up by machine learning.

Researchers from Harvard Medical School found that it is the changes that affect the expression of the DNA — called epigenetics — that affect aging. The discovery may pave the way for more insights into how humans age.

The last few years have exceeded all expectations in terms of investment activity in longevity, but much more is needed to push the field forward. With more than 40 investments in the longevity field over the past three years, LongevityTech.fund is one of the world’s most active longevity investment funds. The fund’s wide-ranging investment portfolio includes companies like BrainKey, Gerostate Alpha and Occuity.

LongevityTech.fund is now accepting new investors for its second fund, with a target fund size of $50 million up to a maximum of $100 million USD.

Longevity. Technology: LongevityTech.fund has built an impressive company portfolio that has seen no failures to date, with one IPO (longevity biotech Genflow Biosciences) and one company (longevity risk management firm Vesttoo) recently becoming the fund’s first unicorn (valued at more than $1 billion). To learn more about his views on the longevity market, we spoke to serial entrepreneur and investor Petr Sramek, LongevityTech.fund’s co-founder and managing partner.

Healthy mutant gene in super-fit people can reverse the decline of heart performance in the elderly, according to a study.

Injecting the genes of so-called “super-agers” into failing heart cells regenerates them, making them function as if they were 10 years younger, scientists have found.

The discovery opens the door for heart failure to be treated or prevented by reprogramming damaged cells.

The hypertension drug rilmenidine has been shown to slow down aging in worms, an effect that in humans could hypothetically help us live longer and keep us healthier in our latter years.

Rilmenidine was picked for this latest study because past research has shown it mimics the effects of caloric restriction on a cellular level. Reducing available energy while maintaining nutrition within the body has been shown to extend lifespans in several animal models.

Whether this translates to human biology, or is a potential risk to our health, is a topic of ongoing debate. Finding ways to achieve the same benefits without the costs of extreme calorie cutting could lead to new ways to improve health in old age.